From Mike Lee U.S. Senator of Utah July 13, 2023, WASHINGTON – Sens. Mike Lee (R-UT), Ben Ray Luján (D-NM), Mike Braun (R-IN), and J.D. Vance (R-OH) introduced the Biosimilar Red Tape Elimination Act to increase competition within the biological drug market and increase access to low-cost prescription drugs. <Read Full Article>… Continue reading
From BioBuzz by Workforce Genetics By Steven Surdez 12AUG2022 A key recent hire for BioFactura was biosimilars and scientific affairs expert Rodeina Challand, who joined the team as its new VP of Scientific Affairs in late 2021. We caught up with Challand to discuss her background, the biosimilars market landscape, and why she’s excited about what’s next … Continue reading
From Generics Bulletin/Informa Pharma Intelligence By Dean Rudge 14SEP2021 BioFactura, which is already using its ‘StableFast’ technology platform to develop its biosimilar ustekinumab candidate, has allied with fellow US-based biotech Rani Therapeutics to see if the biologic can be formulated into Rani’s proprietary ‘robotic’ pill. <Read Full Article>… Continue reading
From U.S. Department of Health and Human Services By DHHS 26SEP2019 The U.S. Department of Health and Human Services will sponsor development of a novel therapeutic to treat smallpox infections. The variola virus, which causes smallpox was eradicated but remains a potential health security threat… Read Full Artic… Continue reading